Patents Issued in February 1, 2024
  • COMPOSITIONS AND METHODS FOR ALTERING THE COLOR OF HAIR
    Publication number: 20240033198
    Abstract: The disclosure relates to compositions for altering the color of keratin fibers and methods of using the compositions. The compositions comprise (a) a bonding system comprising (i) at least one first bonding agent chosen from lactic acid and/or salts thereof, and (ii) at least one second bonding agent chosen from amino acids and/or salts thereof; (b) at least one fatty alcohol; (c) at least one fatty acid; (d) at least one alkyl polyglucoside; (e) at least one alkalizing agent; and (f) at least one solvent. The compositions can further comprise one or more oxidation dyes, couplers, oxidizing agents, or combinations thereof.
    Type: Application
    Filed: July 31, 2022
    Publication date: February 1, 2024
    Inventors: Shahid Mohammad NASEER, Aakash Jagat PAREKH, Sivaramakrishnan MUTHUKRISHNAN
  • HAIR TREATMENT METHOD THAT INCREASES THE BOND DENSITY OF DAMAGED HAIR
    Publication number: 20240033199
    Abstract: Keratinic fiber treatment methods that increase the bond density of damaged hair are disclosed, the methods include the application to the hair of potassium azeloyl diglycinate in weight percentages ranging between 0.1 and 6%, preferably between 0.5 and 3%.
    Type: Application
    Filed: July 19, 2023
    Publication date: February 1, 2024
    Applicant: BEAUTY & BUSINESS S.p.A.
    Inventors: Giovanni Villa, Emanuela Facchetti
  • SEMI-PERMANENT TATTOOS
    Publication number: 20240033200
    Abstract: The present disclosure relates to semi-permanent tattoos, for example, compositions comprising semi-permanent colorants and semi-permanent colorant precursors that include derivatives of genipin and lawsone. In some embodiments, the composition comprises: a semi-permanent colorant present in an amount of about 10% to about 20% w/w of the composition; a solvent present in an amount of about 65% to about 80% w/w of the composition; and a thickening agent present in an amount of 0.01% to about 0.3% w/w of the composition. In some embodiments, the composition further includes one or more of a film-forming agent, a humectant, and a preservative.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 1, 2024
    Applicant: Inkbox Ink Inc.
    Inventors: Christopher B. CAPUTO, Sanjay MANHAS, Ian MALLOV, Ingrid UM NLEND, Fiona JEEVA, Tyler J. HANDLEY, Charley Nicole GARRARD
  • COMPOSITION COMPRISING POLYION COMPLEX PARTICLE AND FILLER
    Publication number: 20240033201
    Abstract: The present invention relates to a composition comprising: (a) at least one particle, comprising at least one cationic polymer and at least one anionic polymer, and at least one non-polymeric acid having two or more pKa values or salt(s) thereof; (b) at least one filler; and (c) water. The composition according to the present invention can provide improved an moisturizing texture, preferably a combination of an improved moisturizing texture and mattifying effect.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 1, 2024
    Inventors: Shinobu MITSUDA, Hiroyuki OGATA
  • COSMETIC COMPOSITION AND METHODS OF USE THEREOF
    Publication number: 20240033202
    Abstract: Disclosed is a topical skin composition. The composition can include water, caprylic/capric triglyceride, Butyrospermum parkii (shea) butter, Helianthus annuus (sunflower) seed oil, cetyl alcohol, glyceryl stearate, and beeswax.
    Type: Application
    Filed: April 4, 2023
    Publication date: February 1, 2024
    Inventors: Julia COLLIER, Michael FRUSHOUR, Kim WILSON
  • INVERSE EMULSION COMPRISING ETHYL CELLULOSE, AN ETHER OR CARBONATE HYDROCARBON-BASED OIL AND METHOD EMPLOYING SAME
    Publication number: 20240033203
    Abstract: The present invention relates to a composition in the form of a water-in-oil emulsion comprising: ethyl cellulose; at least one first non-volatile oil that is liquid at 25° C., chosen from saturated or unsaturated, linear or branched C10-C26 fatty alcohols; at least one second non-volatile hydrocarbon-based oil that is liquid at 25° C. chosen from ethers of formula ROR?, carbonates of formula RO(CO)OR?, in which formulae the R and R? groups, which may be identical or different, represent a saturated or unsaturated, branched or unbranched, hydrocarbon-based group comprising at most 16 carbon atoms, preferably a C3-C16 group; and also mixtures thereof; at least one first non-ionic hydrocarbon-based surfactant. It also relates to a method for making up and/or caring for human keratin materials, in particular the skin or the lips, and preferably the lips, in which said composition is applied.
    Type: Application
    Filed: December 16, 2021
    Publication date: February 1, 2024
    Inventors: Ludovic MINEAU, Anne-Sophie METIVIER, Roberto CAVAZZUTI, Odile AUBRUN, Marie-Jeanne MANZOLA MAZEKA, Lyubov LUKYANOVA
  • COMPOSITION FOR FORMING COATING
    Publication number: 20240033204
    Abstract: A composition for forming a coating film, including the following components (a), (b), (c), and (d): (a) a polymer having a coating film forming ability, (b) one or more volatile substances selected from the group consisting of alcohols and ketones, (c) a plasticizer; and (d) 3 mass % or more and 15 mass % or less of a non-volatile oil agent, other than the component (c), having a viscosity at 35° C. of 50 mPa·s or more and 3,000 mPa·s or less.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 1, 2024
    Applicant: KAO CORPORATION
    Inventor: Tatsuya YOSHINO
  • ANHYDROUS SOLID COMPOSITION COMPRISING AN ANIONIC SURFACTANT AND A MIXTURE OF CITRIC ACID AND BICARBONATE
    Publication number: 20240033205
    Abstract: The present invention relates to a solid composition intended in particular for washing and/or conditioning keratin fibres, notably human keratin fibres such as the hair, and which comprises an anionic surfactant and a mixture of citric acid and alkali metal or alkaline-earth metal bicarbonate. The invention also relates to a packaging article containing said solid composition, and also to cosmetic processes for treating keratin fibres, in particular human keratin fibres such as the hair, using said solid composition or said packaging article. The invention also relates to the use of said solid composition or of said packaging article for washing and/or conditioning keratin fibres, in particular human keratin fibres such as the hair.
    Type: Application
    Filed: December 3, 2021
    Publication date: February 1, 2024
    Inventors: Christelle MORVAN, Damien DRILLON, Andreia TEIXEIRA
  • SYSTEM AND METHOD FOR PRIMING EYE COSMETICS
    Publication number: 20240033206
    Abstract: Cosmetic compositions, and methods of use, where the cosmetic compositions are multi-purpose oil-in-water emulsions that contain (i) a surfactant system of high HLB surfactants and (ii) a high load of talc. The emulsions are capable of being used as a base for eye cosmetics, in order to enhance wear of eyeshadow and removal of mascara.
    Type: Application
    Filed: October 12, 2023
    Publication date: February 1, 2024
    Applicant: L’ORÉAL
    Inventors: Christopher PANG, Sylvie PORET-FRISTOT
  • TOPICALLY ADMINISTRABLE LYSATE (LY) OF DEDIFFERENTIATED CELLS OF THE PLANT HELICHRYSUM STOECHAS FOR ELIMINATING OR REDUCING INFLAMMATION OF THE SKIN
    Publication number: 20240033207
    Abstract: Disclosed is a lysate of dedifferentiated cells of the plant Helichrysum stoechas, which can be topically administered, for eliminating or reducing inflammation of the skin and/or scalp.
    Type: Application
    Filed: February 15, 2021
    Publication date: February 1, 2024
    Inventors: Erwan LE GELEBART, Cécile BIZE
  • BOTANICAL EXTRACT BLEND FOR USE IN SKIN CARE
    Publication number: 20240033208
    Abstract: Topical compositions containing a decolorized muscadine grape pomace extract, a water extract of Chardonnay grape seed, and resveratrol are disclosed, as well as methods of use thereof. Also disclosed are methods of preparing the topical compositions.
    Type: Application
    Filed: July 27, 2023
    Publication date: February 1, 2024
    Applicant: Shaklee Corporation
    Inventors: Teodoro T. Ianiro, Jillian Friedman
  • HIGH ANTIOXIDANT GRAPE CONCENTRATE AND ITS USE IN COSMETICS
    Publication number: 20240033209
    Abstract: Disclosed are topical cosmetic compositions comprising a fermented grape concentrate having high antioxidant levels, and a cosmetically acceptable ingredient. Also disclosed are methods of using the topical cosmetic compositions to improve a condition or appearance of skin.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 1, 2024
    Applicant: Juice Beauty, Inc.
    Inventors: Karen Behnke, Howard Luria, Julie Castel, Angella Sprauve
  • USE OF A ROSEBUSH EXTRACT AS DEPIGMENTING ACTIVE AGENT
    Publication number: 20240033210
    Abstract: The present invention relates to a non-therapeutic cosmetic use of an extract of a hybrid rosebush obtained by crossing of varieties Meichibon x Delgramaue, as depigmenting and/or lightening and/or whitening active agent. The present invention also relates to a non-therapeutic cosmetic process for depigmenting, lightening and/or whitening keratin materials, in particular the skin, comprising the application of a cosmetic composition comprising, in a physiologically acceptable medium, an extract of a hybrid rosebush obtained by crossing of varieties Meichibon x Delgramaue.
    Type: Application
    Filed: December 13, 2021
    Publication date: February 1, 2024
    Inventor: Chloé CLABAULT
  • EXTRACT OF AT LEAST ONE PLANT OF THE CROCUS SATIVUS SPECIES COMPRISING A HIGH CONTENT OF CROCINS AND A LOW CONTENT OF SAFRANAL, AND COSMETIC USE THEREOF AS ANTIOXIDANT
    Publication number: 20240033211
    Abstract: The present application relates to an extract of at least one plant of the Crocus sativus species comprising (i) at least 20% by dry weight of one of more crocin(s) relative to the total weight of the components of the dry extract and (ii) less than 0.08% by dry weight of safranal relative to the total weight of the components of the dry extract, to the process for preparing same, and the use thereof as an antioxidant.
    Type: Application
    Filed: December 13, 2021
    Publication date: February 1, 2024
    Inventors: Christophe RONDOT, Saliou NGOM
  • COMPOSITION FOR CLEANSING KERATIN MATERIALS
    Publication number: 20240033212
    Abstract: The present invention is targeted at a composition, in particular a cosmetic and non-therapeutic composition, for the care, the hygiene and/or the cleansing of keratin materials, comprising at least (i) all or part of a lysate, isolated or not, from a medium for the fermentation of a non-pathogenic and aerobic proteobacterium or a (glyco)oligopeptide fraction isolated from such a lysate, (ii) at least one mucopolysaccharide, in particular with a weight of greater than 10 kD, and (iii) at least one moisturizing agent distinct from (i) and from (ii), preferably in aqueous formulation and in the presence of electrolytes. It is additionally targeted at a method for care, hygiene and/or cleansing of a keratin material, comprising the use of such a composition.
    Type: Application
    Filed: December 6, 2021
    Publication date: February 1, 2024
    Inventors: Francis PRUCHE, Lucie TOURNIER-COUTURIER
  • TOPICAL PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF SYNDROMES ASSOCIATED WITH CHRONIC PELVIC PAIN
    Publication number: 20240033213
    Abstract: A topical pharmaceutical formulation comprising an aqueous composition comprising cannabinoids, in particular cannabidiol, in niosomes having a size of less than 500 nm, and at least one topically acceptable excipient, for use in the treatment of syndromes associated with chronic pelvic pain, in particular by topical application by means of a dynamic electroporation apparatus.
    Type: Application
    Filed: December 16, 2021
    Publication date: February 1, 2024
    Applicant: CURALEAF INTERNATIONAL LIMITED
    Inventors: Barbara PACCHETTI, Antonio COSTANZO
  • TRANSDERMAL DELIVERY FORMULATIONS
    Publication number: 20240033214
    Abstract: A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.
    Type: Application
    Filed: October 16, 2023
    Publication date: February 1, 2024
    Inventor: Joel M. Friedman
  • INJECTABLE FORMULATION WITH ENHANCED STABILITY CONTAINING DEXIBUPROFEN AND ARGININ AND THEIR MEDICINE VESSEL FOR INJECTION
    Publication number: 20240033215
    Abstract: Disclosed herein are an injectable formulation with improved stability and an injectable formulation with improved storage stability. The injectable formulation with improved stability comprises dexibuprofen and arginine and ranging in pH from 6.5 to 8.5, wherein arginine is contained in an amount of 300 to 500 parts by weight and preferably in an amount of 320 to 330 parts by weight, based on 400 parts by weight of dexibuprofen, and the injectable formulation with improved storage stability is prepared by subjecting the injectable formulation with improved stability to nitrogen substitution and loading the nitrogen-substituted formulation into a storage container, with a saturation oxygen of 5% or less therein.
    Type: Application
    Filed: July 25, 2023
    Publication date: February 1, 2024
    Applicant: AMOS PHARM
    Inventor: Jae Ho CHOI
  • CELL HOUSING DEVICE
    Publication number: 20240033216
    Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of chemicals to increase the ratio of surface area to volume.
    Type: Application
    Filed: September 21, 2023
    Publication date: February 1, 2024
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
  • METHOD OF ORALLY ADMINISTERING A FECAL MICROBIOTA TRANSPLANT COMPOSITION
    Publication number: 20240033217
    Abstract: Disclosures herein relate to a fecal microbiota transplant (FMT) composition for oral delivery, the FMT composition comprising an FMT including desired fecal microbes, wherein the FMT has an odor as evaluated with a confidence of 95% to be odorless for more than 50% of the population using a triangular test, wherein the FMT has a flavor as evaluated with a confidence of 80% to be flavorless for more than 50% of the population using the triangular test.
    Type: Application
    Filed: August 1, 2023
    Publication date: February 1, 2024
    Inventor: Jason Bernard Klop
  • DIHYDROERGOTAMINE DRY POWDER FORMULATIONS AND METHODS OF USE
    Publication number: 20240033218
    Abstract: The present disclosure relates to dry powder formulations comprising respirable dry particles that comprise 1) dihydroergotamine (DHE) or a salt, hydrate, or polymorph thereof, 2) a monovalent metal cation salt, and 3) one or more excipients; and also relates to methods of using the dry powder for the treatment of a migraine, headache, or a symptom thereof, methods of making the dry powder, and receptacles and devices containing the dry powder.
    Type: Application
    Filed: March 1, 2022
    Publication date: February 1, 2024
    Inventors: Jason M. PERRY, Aidan K. CURRAN, Aaron C. GONZALEZ NELSON, Dayna F. HANSON, Hillary T. BERGSON, Eric C. STOLZ
  • COMPOSITIONS AND METHODS FOR MUCOSAL DRUG DELIVERY
    Publication number: 20240033219
    Abstract: Disclosed herein are polymers, nanoparticles, and pharmaceutical compositions and formulations that are useful for topical delivery of therapeutic agents to an eye of an subject in need thereof.
    Type: Application
    Filed: December 8, 2021
    Publication date: February 1, 2024
    Inventors: Nasim Annabi, Reza Dana, Shima Gholizadeh
  • METHOD AND DEVICE FOR PRODUCING A LIQUID CONTAINING LIPOSOMES, AND PRODUCED LIQUID
    Publication number: 20240033220
    Abstract: A method and a device for producing a liquid containing liposomes is presented. The method comprises the conduction of a first liquid and a second liquid into a micromixer and to the output of the micromixer by gas pressure from at least one source of gas. The total flow rate of the liquids is adjusted in such a way that the total flow rate at the output of the micromixer is at least 10 mL/min. This allows the production of liquids, which contain liposomes having a narrow size distribution, on an industrial scale in a simple and reproducible manner. The embodiments also include a liquid containing liposomes having a narrow size distribution and to uses thereof.
    Type: Application
    Filed: May 19, 2023
    Publication date: February 1, 2024
    Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Regina Bleul, Raphael Thiermann
  • LONG-ACTING BUPIVACAINE MICROSPHERE FORMULATIONS
    Publication number: 20240033221
    Abstract: According to various aspects of this disclosure, the present disclosure relates to long-acting, shelf-stable microsphere formulations of bupivacaine, kits, and methods for treating or preventing pain by parenteral injection of a microsphere formulation of bupivacaine.
    Type: Application
    Filed: April 22, 2021
    Publication date: February 1, 2024
    Inventors: Shankar HARIHARAN, Suketu SANGHVI, Rahul SURANA, Maarten van DIJK, Ivan TERZIC, Kimberly Aniek BANUS, Thanh NGUYEN, Rob STEENDAM
  • AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE
    Publication number: 20240033222
    Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an ?-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 1, 2024
    Applicant: NORTON (WATERFORD) LIMITED
    Inventors: Brian Paul O'NEILL, Hardik Kirtikumar SHAH, Julian Alexander BLAIR, Chris David EDLIN, Shane Michael MCKEON
  • FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION
    Publication number: 20240033223
    Abstract: The present disclosure relates to a fosphenytoin sodium solid composition, a lyophilization method of fosphenytoin sodium, and use of the fosphenytoin sodium solid composition. The fosphenytoin sodium solid composition comprises fosphenytoin sodium and at least one carbohydrate. The fosphenytoin sodium solid composition prepared in the present disclosure is stable and can be stored at room temperature. In addition, the lyophilization method for the fosphenytoin sodium is short in lyophilization time, the product obtained by the present method does not collapse, the reconstitution time is short, and the moisture content satisfies the quality requirements. The fosphenytoin sodium solid composition can be used for treatment of epilepsy or other convulsion states.
    Type: Application
    Filed: December 4, 2020
    Publication date: February 1, 2024
    Inventors: Gang CHEN, Gongzheng CHEN, Song LIN, Kaliappanadar NELLAIAPPAN, Indu JAVERI
  • ENTERIC-COATED PELLET, METHOD FOR PREPARING SAME AND FORMULATION COMPRISING SAME
    Publication number: 20240033224
    Abstract: An enteric-coated pellet, a method for preparing the same and a formulation comprising the same are provided. The enteric-coated pellet can be an ilaprazole enteric-coated pellet.
    Type: Application
    Filed: November 12, 2021
    Publication date: February 1, 2024
    Inventors: Pucheng LI, Yating MO, Xiangna ZHANG, Xuemei HOU, Yannan CUI, Siwen HU, Caihua CHENG, Weishan LIN, Zengqing TU, Yurong ZHANG, Hongdan SHEN, Shenchao JIAO, Yang FENG, Zhihui HAN, Lei WU, Zhuanxia ZHANG
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240033225
    Abstract: The present invention provides for a method of treatment of IgA nephropathy, which method comprises: (i) identifying a pharmaceutically acceptable composition intended to treat IgA nephropathy comprising budesonide and one or more pharmaceutically-acceptable excipients that provide for a modified release of said budesonide after administration to the gastrointestinal tract, which composition fulfils the following requirements in a standard in vitro USP<711>/Ph.Eur. 2.9.3 dissolution test using a dissolution apparatus according to Apparatus 2 (Paddle Apparatus) of said test; (a) the composition fulfils the requirement that no more than about 10% of the budesonide is released into the dissolution medium within about 120 minutes, when the dissolution medium is aqueous and has a pH of about 1.
    Type: Application
    Filed: July 14, 2023
    Publication date: February 1, 2024
    Inventors: Andrew STONE, Jens KRISTENSEN, Richard PHILIPSON, Eva Kristina RIESEL, Lena Margareta PERESWETOFF-MORATH, Kari SANDVOLD, Christian Olle Andreas PEDERSEN
  • CHITOSAN-Fe COATING-BASED SYNBIOTIC MICROCAPSULE WITH GASTRIC ACID RESISTANCE AND INTESTINAL TARGETED RELEASE AND PREPARATION METHOD THEREOF
    Publication number: 20240033226
    Abstract: The present disclosure provides a chitosan-Fe coating-based synbiotic microcapsule with gastric acid resistance and intestinal targeted release and a preparation method thereof. The preparation method includes the following steps: preparation of mixed probiotics, preparation of a chitosan-Fe coating, preparation of a microcapsule, and freeze-drying. In the present disclosure, live probiotics wrapped in the microcapsule can avoid a weak acid resistance and a poor long-term storage stability of the probiotics; chitosan-Fe added to a wall material can significantly improve an embedding rate of the microcapsule, and can also achieve targeted release of the probiotics in the intestinal tract.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 1, 2024
    Inventors: Yi Wu, Ling Guo, Zeyu Zhang, Dongli Ma, Zhiguo Xing, Liming Xia
  • COMPOSITIONS FOR FACILITATING MEMBRANE FUSION AND USES THEREOF
    Publication number: 20240033227
    Abstract: In some aspects, fusosome compositions and methods are described herein that comprise membrane enclosed preparations, comprising a fusogen. In some embodiments, the fusosome can fuse to the target cell, thereby delivering complex biologic agents to the target cell cytoplasm.
    Type: Application
    Filed: January 13, 2023
    Publication date: February 1, 2024
    Inventors: Geoffrey A. von Maltzahn, John Miles Milwid, Michael Travis Mee, Jacob Rosenblum Rubens, Nathan Wilson Stebbins, Molly Krisann Gibson, Neal Francis Gordon, Bo Zhang, Kyle Marvin Trudeau, Brigham Jay Hartley, Tamar Rose Putiri, Kiana Mahdaviani, Matthew Milnes Dobbin
  • MESOPOROUS NANOPARTICLES SYSTEM TO INCREASE THE BIOFILM ERADICATION ACTIVITY BY MEANS OF THE CARRYING AND THE ADMINISTRATION OF AT LEAST ONE ACTIVE INGREDIENT AND RELATED PRODUCTION METHOD
    Publication number: 20240033228
    Abstract: A system for the administration and delivery of active ingredients includes a vector or carrier chosen from the mesoporous nanoparticles and one or more pharmacologically active ingredients (API) including molecules with antibacterial, bacteriostatic or bactericidal and/or mucolytic and/or anti-inflammatory activity, loaded and/or supported in said vector, in which said vector is constituted by mesoporous particles of zirconia (MZN).
    Type: Application
    Filed: October 7, 2021
    Publication date: February 1, 2024
    Inventors: Emmanuele Kizito AMBROSI, Benedetta LEONETTI, Andrea CASTELLIN, Gabriele SPONCHIA
  • USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20240033229
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Application
    Filed: February 16, 2023
    Publication date: February 1, 2024
    Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Anne COMI
  • COMPOSITIONS FOR THE TREATMENT OF BLEPHARITIS
    Publication number: 20240033230
    Abstract: Embodiments relate to a method for treatment of blepharitis in a patient in need thereof comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically effective amount of at least one cannabinoid, via the topical route. Optionally, the pharmaceutical composition is administered in combination with an additional agent selected from the group consisting of: an essential oil, a steroid, an antibiotic, an anti-parasitic, a disinfectant, an anesthetic, a terpene, a moisturizer and a vitamin.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 1, 2024
    Inventors: Michael RUBINOV, Greg RUBIN
  • COMPOSITION FOR INHIBITING PARKINSON'S DISEASE AND METHOD OF MANUFACTURING THE SAME
    Publication number: 20240033231
    Abstract: A composition for inhibiting Parkinson's disease is provided, comprising 1 part by weight of soybean oil, 5 to 14 parts by weight of an emulsifier, 0.5 to 2 parts by weight of lecithin, 81 to 91 parts by weight of deionized water, and 2.345 to 17.833 parts by weight of cinnamaldehyde. Furthermore, the present invention also provides a method for manufacturing the composition for inhibiting Parkinson's disease, to produce the aforementioned composition for inhibiting Parkinson's disease.
    Type: Application
    Filed: July 26, 2023
    Publication date: February 1, 2024
    Inventors: Bing-Huei CHEN, Yi-Chun WANG, Yung-Sheng CHANG, Tai-Yi HE
  • New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome
    Publication number: 20240033232
    Abstract: This invention disclosed new use of (R)-enantiomer ?2-agonists such as (R)-terbutaline and (R)-salbutamol in treatment of sepsis, sepsis related multiple organ failure and acute respiratory destress syndrome.
    Type: Application
    Filed: March 10, 2021
    Publication date: February 1, 2024
    Inventor: Wen TAN
  • COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS
    Publication number: 20240033233
    Abstract: Provided herein are compositions and methods for delivering pharmaceutical agents. In particular, provided herein are topical formulations of resatorvid for use in treating and preventing skin pathologies.
    Type: Application
    Filed: July 30, 2021
    Publication date: February 1, 2024
    Inventors: Heidi Mansour, Victor Ruiz, Sally E. Dickinson, Clara N. Curiel, Hsiao-Hui Chow, Georg T. Wondrak
  • THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOF
    Publication number: 20240033234
    Abstract: The present disclosure, in part, is directed to compositions comprising a compound of formula (I): wherein the compositions are substantially free of an impurity, processes of producing thereof, and uses thereof.
    Type: Application
    Filed: August 9, 2023
    Publication date: February 1, 2024
    Inventors: Imran Alibhai, Sofia de Achaval, Alan Millar
  • COATED BETA HYDROXYBUTYRIC ACID CRYSTAL AND METHODS FOR PRODUCING THE SAME
    Publication number: 20240033235
    Abstract: Coated beta-hydroxybutyrate (BHB) free acid crystal pellets/granules are provided, which comprise BHB free acid crystal, fillers, and coating material. Methods for producing coated BHB free acid crystal pellets/granules are provided, which may include (a) wet granulation, (b) extrusion, (c) spheronization, and (d) coating, such as coating material spray embedding through Wurster bottom spray coating device.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 1, 2024
    Inventors: Long JIANG, Yang ZHU, Ronghua YI, Kylin LIAO
  • METHODS OF TREATING HERPES VIRAL INFECTION WITH 4-PHENYLBUTYRATE (PBA) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20240033236
    Abstract: Disclosed herein are compositions comprising: 4-phenylbutyrate (PBA) or a pharmaceutically acceptable salt thereof in an effective concentration as a therapeutic or prophylactic agent against viral infections, e.g., herpes simplex vims (HSV) infections. Also provided are methods for treating a disease or disorder in a subject, such as a viral infection (e.g., HSV infection), comprising administering to the subject a therapeutically or prophylactically effective amount of 4-phenylbutyrate (PBA) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 13, 2021
    Publication date: February 1, 2024
    Inventors: Tejabhiram Yadavalli, Deepak Shukla
  • USE OF A-KETOGLUTARATE IN MANUFACTURE OF MEDICAMENT
    Publication number: 20240033237
    Abstract: The use of ?-KG in the manufacture of a medicament, the medicament being used for: 1) treating osteoarthritis and related diseases; and/or, 2) inhibiting the catabolic phenotype of chondrocytes; and/or, 3) promoting the synthetic phenotype of chondrocytes; and/or, 4) promoting the regeneration of skin hair follicles. A pharmaceutical composition provided by the present disclosure can protect cartilage tissue and impede the progression of osteoarthritis, thus having great potential application for the clinical treatment and prevention of osteoarthritis. Further, the medicament provided by the present disclosure can significantly increase the number of skin hair follicles, which also has great potential application value for the treatment and improvement of hair loss.
    Type: Application
    Filed: December 23, 2020
    Publication date: February 1, 2024
    Applicant: TONGJI UNIVERSITY
    Inventors: Lei CUI, Shuaijun LI
  • COMBINATION OF COMPOUNDS FOR USE IN THERAPY
    Publication number: 20240033238
    Abstract: The present invention relates to a combination of compounds for a use in therapy and especially to a therapeutic combination for use in the treatment of tumours and/or cancer. In particular, the invention relates to a therapeutic combination that comprises a NKCC1 protein inhibitor and a microtubule inhibitor, optionally together with one or more additional chemotherapeutic agents or radiotherapy. The combined administration includes at least one NKCC1 protein inhibitor and at least one microtubule inhibitor.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 1, 2024
    Applicant: B&A ONCOMEDICAL
    Inventors: Yehezkel BEN-ARI, François BERGER
  • CYSTEINE COMPOSITION AND INJECTION
    Publication number: 20240033239
    Abstract: Cysteine compositions comprising less than about 400 ?g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 ?g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.
    Type: Application
    Filed: October 5, 2023
    Publication date: February 1, 2024
    Inventors: Angela Sutterer, Jill Simpson, Gauthier Pouliquen, Alain Constancis, Pierre Danner
  • DUAL RESPONSIVE BRAIN TARGETED NANOPARTICLES FOR USE IN TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20240033240
    Abstract: The preparation of dual functionalized nanoparticles is generally provided along with their application. The dual functionalized nanoparticles provide dual targeting and can effectively pass the blood brain barrier and target brain tissue. The dual targeted and dual responsive nanoparticles are functionalized to include at least two different ligands that are capable of transport across the blood brain barrier. The nanoparticles can be prepared from polymeric materials that can be biocompatible, provide long circulation life in a body, and be successfully ligated to both functionalities by use of acid-sensitive and/or redox potential-sensitive bonds for delivery across the blood brain barrier and delivery of a payload to brain tissue.
    Type: Application
    Filed: October 2, 2023
    Publication date: February 1, 2024
    Inventors: Peisheng Xu, Eleni Markoutsa
  • COMPOSITION FOR EXTERNAL USE ON SKIN FOR INFLAMMATORY DISEASES
    Publication number: 20240033241
    Abstract: [Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 1, 2024
    Inventors: Jiro TAKEO, Hiroyuki KAWAHARA
  • IMMUNOREGULATORY MICROPARTICLES FOR MODULATING INFLAMMATORY ARTHRITIDES
    Publication number: 20240033242
    Abstract: Described herein are compositions and methods for treating inflammatory arthritic conditions tint are effective systemically without causing generalized immunosuppression when administered locally into an inflammatory arthritis-affected joint or a draining lymph node of the arthritis-affected joint of a patient.
    Type: Application
    Filed: September 25, 2023
    Publication date: February 1, 2024
    Inventors: Nisarg Shah, David A. McBride, Nunzio Bottini
  • METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS
    Publication number: 20240033243
    Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.
    Type: Application
    Filed: May 12, 2023
    Publication date: February 1, 2024
    Inventors: Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi
  • COMPOSITIONS AND METHODS FOR INHIBITING YTHDF1
    Publication number: 20240033244
    Abstract: A YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) attenuating agent, with a compound, and when bound to YTHDF1, the compound binds to amino acid residues 372-392, 479-494 and 526-535 of SEQ ID NO: 1. A modified antigen presenting cell (mAPC), with the mAPC being treated with a YTHDF1 attenuating agent. A composition, with a YTHDF1 attenuating agent, a mAPC treated with the YTHDF1 attenuating agent, and optionally a pharmaceutically acceptable carrier. A method for attenuating an activity of YTHDF1, by administering an effective amount of a YTHDF1 attenuating agent. A method for determining whether or not a candidate agent is a YTHDF1 attenuating agent, by contacting the candidate agent with a YTHDF1 mutant. A method for treating a disease, disorder or condition associated with an expression of an antigen in a subject in need thereof.
    Type: Application
    Filed: July 8, 2021
    Publication date: February 1, 2024
    Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, HANGZHOU LEADING EDGE PHARMACEUTICAL LTD., SHANGHAI KANGQIAN BIOTECHNOLOGY LIMITED
    Inventors: Cheng LUO, Meng XU, Shijie CHEN, Yilin LI, Yantao CHEN, Hualiang JIANG, Kaixian CHEN, Zhanpeng JIANG
  • Prevention and Treatment of Viral Infections
    Publication number: 20240033245
    Abstract: The present disclosure targets West Nile virus, Respiratory Syncytial Virus, and other disease-causing microbes, including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.
    Type: Application
    Filed: January 12, 2023
    Publication date: February 1, 2024
    Inventor: Steven BARANOWITZ
  • COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS
    Publication number: 20240033246
    Abstract: The invention concerns 3,5,4?-trihydroxy-6,7,3?-trimethoxyflavone (TTF) or a pharmaceutically acceptable salt or solvate thereof for use in treating, preventing, or ameliorating an eye disease or disorder, or for providing adjunct treatment to an ocular therapeutic procedure. The invention also concerns ophthalmic compositions comprising TTF.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 1, 2024
    Inventors: Anat Elmann, Ygal Rotenstreich, Ifat Sher
  • USE OF COMPOSITION IN TREATMENT OF CEREBRAL STROKE
    Publication number: 20240033247
    Abstract: Use of a composition in preparation of a drug for treating a patient suffering from a cerebral stroke. The composition includes edaravone and dexborneol, and the patient has a history of hypertension.
    Type: Application
    Filed: July 7, 2021
    Publication date: February 1, 2024
    Inventors: Xiaofei Feng, Shunwei Zhu, Cuncun Liu, Feng Wang, Jinsheng Ren